Valneva SE
VALN
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.72
Price-2.00%
-$0.18
1Y
Price
Market Cap
$688.091m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-12.8%
EBITDA Margin-24.0%
Net Profit Margin-8.4%
Free Cash Flow MarginRevenue
$196.327m
+15.8%
1y CAGR-10.5%
3y CAGR-6.9%
5y CAGREarnings
-$67.041m
-447.4%
1y CAGR-110.1%
3y CAGR-106.3%
5y CAGREPS
-$0.92
-441.2%
1y CAGR-103.9%
3y CAGR-94.3%
5y CAGRBook Value
$186.432m
$472.625m
Assets$286.193m
Liabilities$196.924m
DebtDebt to Assets
41.7%
-4.7x
Debt to EBITDAFree Cash Flow
-$34.389m
+58.9%
1y CAGR+47.1%
3y CAGR-361.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company